AACC’s 65th Annual Meeting & Clinical Lab Expo was held at McCormick Place in Chicago from July 27-31. Block Scientific participated in this prestigious event which, according to a recently released AACC report, was attended by about 20,000 medical professionals and healthcare leaders. The Clinical Lab Expo had more than 700 exhibitors displaying breakthrough innovations in diagnostic research and technology indicative of the rapid advances in laboratory equipment and medicine.

AACC Clinical Lab Meeting

Among the major achievements showcased were state-of-the-art devices that integrate multiple laboratory functions on a single chip or ‘lab-on-a-chip technology’, the first ever human papillomavirus DNA test approved by the Food and Drug Administration for primary cervical cancer screening, and new tests in reproductive health, infectious diseases, drug testing, and more.

Some of the novel and exciting topics that featured in the sessions were:

  • How miRNAs could impact on clinical practice and possibly function as therapeutic targets because of their powerful role in many diseases
  • Use of mass spectrometry to identify a panel of lipids in blood that could predict preclinical Alzheimer’s disease
  • The emergence of synthetic cannabinoids and other designer drugs which do not produce positive screening results on traditional cannabinoid immunoassays
  • Plasma genomic and methylomic sequencing for cancer detection
  • Ways in which next-generation sequencing technologies are guiding targeted cancer therapy
  • The relationship between the quality of interpretive comments and patient outcomes
  • How big data analysis can revolutionize healthcare with new evaluation approaches

Abstracts presented at the meeting highlighted timely discoveries in the field of laboratory medicine, including research on a portable blood test that can detect low levels of Ebola and the Sudan virus in just 10 minutes. As it uses technology similar to home pregnancy tests and does not require extensive medical training to perform, the test can be performed in the resource-limited settings most prone to Ebola outbreaks.